Head to Head Contrast: Verastem (NASDAQ:VSTM) & Biogen (NASDAQ:BIIB)

Biogen (NASDAQ:BIIB) and Verastem (NASDAQ:VSTM) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Institutional and Insider Ownership

87.9% of Biogen shares are owned by institutional investors. Comparatively, 88.4% of Verastem shares are owned by institutional investors. 0.3% of Biogen shares are owned by company insiders. Comparatively, 1.9% of Verastem shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

Biogen has a beta of 0.1, meaning that its share price is 90% less volatile than the S&P 500. Comparatively, Verastem has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500.

Earnings & Valuation

This table compares Biogen and Verastem”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$10.30 billion	3.60	$1.29 billion	$2.34	107.30
Verastem	$30.91 million	23.62	-$209.47 million	($2.05)	-3.93

Biogen has higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Biogen and Verastem’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biogen	3.37%	9.38%	5.69%
Verastem	-178.38%	-359.49%	-78.60%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Biogen and Verastem, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1	10	21	1	2.67
Verastem	1	1	11	0	2.77

Biogen currently has a consensus target price of $254.41, indicating a potential upside of 1.32%. Verastem has a consensus target price of $16.83, indicating a potential upside of 108.77%. Given Verastem’s stronger consensus rating and higher possible upside, analysts plainly believe Verastem is more favorable than Biogen.

Summary

Biogen beats Verastem on 9 of the 15 factors compared between the two stocks.

About Biogen

Biogen is a biotechnology company focused on developing and commercializing medicines for neurological and rare diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy and Friedreich’s ataxia. Its products include multiple sclerosis treatments such as Tysabri, Tecfidera and Vumerity, and Skyclarys for Friedreich’s ataxia. Biogen shares rights to several medicines with other companies, including Leqembi for Alzheimer’s disease with Eisai and Spinraza for spinal muscular atrophy with Ionis Pharmaceuticals.

About Verastem

Verastem, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for cancer. Its research has centered on signaling pathways involved in tumor growth, including the RAS/MAPK pathway. The company’s product, AVMAPKI FAKZYNJA CO-PACK, combines avutometinib and defactinib. The U.S. Food and Drug Administration approved the combination for certain adults with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy. Verastem is based in Needham, Massachusetts, and also develops investigational cancer therapies, including potential uses of avutometinib in combination with other medicines.